Why the Pro Medicus (ASX:PME) share price is up 3% in a week

It's been a good few days for the provider of medical imaging software. We take a closer look

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price continues its run into the green today.

Pro Medicus shares are changing hands at $59.60 apiece in afternoon trading, up 1.2% on the day.

Let's take a look at the tailwinds behind the company's share price.

But first, a quick recap on Pro Medicus

Pro Medicus is a provider of medical imaging software to clinics and hospitals.

Its footprint is in Australia, North America, and Europe, supplying radiology information and imaging systems to these markets.

At the time of writing, Pro Medicus has a market capitalisation of $6.1 billion.

What has Pro Medicus been up to lately?

Pro Medicus shares have set two all-time highs recently, including today, when prices reached an intraday high of $60.55.

The momentum behind the company's share price has been gathering steam since the beginning of the year.

Back in January, the company announced it had signed a 7-year contract with Salt Lake City company Intermountain Healthcare.

According to Pro Medicus, the deal will yield a total of $40 million spread over the 7 years.

Following this, the company also announced that its US subsidiary Visage Imaging had confirmed a collaboration with the University of Vermont.

Under the agreement, Pro Medicus will install and roll out its systems in six hospitals under the University's control.

Moreover, it was revealed back on 3 June that Pro Medicus entered into an agreement with the US research giant Mayo Clinic through Visage.

The focus of this deal is to develop and commercialise Pro Medicus' artificial intelligence algorithm, the Visage AI Accelerator platform.

Since this fundamental momentum began in January, Pro Medicus shares have climbed 74% this year to date.

This has extended into the previous 5 trading sessions, in which the company has walked a further 3.5% into the green.

Therefore, while there has been no market sensitive information from the company since June, it stands to reason that investors continue to buy Pro Medicus shares on the back of these advancements in the company's growth engine.

Pro Medicus share price snapshot

The Pro Medicus share price has posted an impressive return of 140% over the previous 12 months.

This has outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of 21% over the same period.

The company also pays a 14 cents per share dividend, giving a current yield of 0.22%.

Should you invest $1,000 in Woolworths Group Limited right now?

Before you buy Woolworths Group Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Woolworths Group Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices.
Broker Notes

Macquarie tips 20% upside for this ASX 200 industrials stock

Let's see what the broker is saying about this stock following an update.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Gold

3 reasons this ASX 200 gold mining giant could soar higher into 2026

A leading expert forecasts more outperformance from this surging ASX 200 gold stock.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Bank Shares

CBA shares hit a new $176 record high. Too late to buy?

What can stop this bank now?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why James Hardie, Mayne Pharma, Nufarm, and Resimac shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Share Gainers

Why Adriatic Metals, Catapult, Seek, and TechnologyOne shares are racing higher today

These shares are having a good time on hump day. But why?

Read more »

a group of business people sit dejectedly around a table, each expressing desolation, sadness and disappointment by holding their head in their hands, casting their gazes down and looking very glum.
Mergers & Acquisitions

This ASX 300 share is sinking 33% on takeover collapse fears

Is this takeover dead? Let's find out what is happening.

Read more »

Mum playing with her baby boy holding him on her tummy as she lays down while smiling about the Bubs share price going up today
Broker Notes

Macquarie tips 80% upside for this ASX All Ords healthcare stock

This out of favour stock could be primed for a rebound.

Read more »